Marllor Biomedical, the Italian manufacturer of Aqualyx, is hosting an event in London to officially launch Alidya.
The company explains that Alidya is the first class III, CE marked, medical device specifically developed to treat cellulite. The injectable was first released in Italy in 2012 and is present in 50 countries to treat grade 1 and 2 cellulite effectively.
Alidya can be used as a stand alone treatment or in combination with other modalities such as carboxytherapy or energy-based devices.
Matteo Fabbri, business development director of Marllor Biomedical, said, “Alidya fills an existing gap in treating cellulite, still one of the most intolerable aesthetic concerns for women. We are very excited to launch Alidya in the UK, as part of our expansion strategy, and we are convinced this will be a game changer for both practitioners and patients alike.”
The event is to be held at Café Royal in Regent Street, London on December 3 and will feature speakers from different countries that will share their experiences with Alidya.
